Biobrit

Creyon Bio is a pre-clinical stage company focused on advancing drug development through a data-driven methodology. It specializes in engineering RNA-based medicines and their components by creating proprietary datasets that inform advanced machine learning models. This innovative approach enables the rapid identification of design rules and engineering principles necessary for the development of safe and effective oligonucleotide-based medicines. By leveraging these insights, Creyon Bio aims to improve the efficiency of the drug development process, ultimately contributing to cost savings in the healthcare sector while catering to diverse patient populations.

Basilard BioTech is a developer of a nanomechanical gene delivery platform aimed at revolutionizing the cell-based therapies market. The company focuses on leveraging the power and diversity of cell functions to address significant unmet clinical needs, particularly in the realm of Cell and Gene Therapies (CGT). By employing a mechanical approach to gene delivery, Basilard BioTech consistently achieves superior transfection rates, enhanced cell viability, and improved yields compared to traditional biological methods. This innovative technology positions the company to significantly advance therapeutic outcomes for diseases that impact millions of individuals globally.

Amplo Biotechnology is a biopharmaceutical company focused on developing innovative Adeno-Associated Viral (AAV) therapies aimed at treating defects related to the neuromuscular junction. These defects can lead to severe health issues, including paralysis and difficulties with breathing and swallowing. The company's lead program, AAV-Dok7, was created by Professor Yuji Yamanashi's research team at the Institute of Medical Science at the University of Tokyo, and it holds promise for addressing various congenital myasthenic syndromes and other rare, severe diseases. Amplo's therapies are administered through intravascular injection, which initiates specific molecular events necessary for effective treatment, thereby enhancing the potential for curative outcomes in affected patients.

Stuart Therapeutics is a biotechnology company focused on developing innovative therapies for ophthalmic conditions. The company's primary offering, PolyCol, is a synthesized peptide therapeutic platform designed to repair disease-damaged helical collagen in the eye. This platform facilitates accelerated healing of epithelial cells, restoration of nerve function, and reduction of inflammation, making it a promising treatment for various ophthalmic diseases, including dry eye disease, dry age-related macular degeneration, and glaucoma. PolyCol is based on patented research from a major U.S. university, supplemented by additional intellectual property acquired by the company. Beyond ophthalmic applications, Stuart Therapeutics is also exploring PolyCol's potential in treating gastrointestinal, inflammatory, and oncology conditions.

Primmune Therapeutics is a biotechnology company developing orally administered small molecule toll-like receptor 7 (TLR7) agonists to stimulate innate immunity in cancer immunotherapy. The TLR7 agonists aim to activate systemic innate immune responses, promoting cytokine and chemokine production, NK cell activation, and B-cell proliferation to support anti-tumor activity. The company intends to combine these agents with adaptive cancer therapies such as checkpoint inhibitors to improve response rates and durability, and targets metastatic cancers.

Primmune Therapeutics is a biotechnology company developing orally administered small molecule toll-like receptor 7 (TLR7) agonists to stimulate innate immunity in cancer immunotherapy. The TLR7 agonists aim to activate systemic innate immune responses, promoting cytokine and chemokine production, NK cell activation, and B-cell proliferation to support anti-tumor activity. The company intends to combine these agents with adaptive cancer therapies such as checkpoint inhibitors to improve response rates and durability, and targets metastatic cancers.

Castle Biosciences is a molecular diagnostics company headquartered in Friendswood, Texas, that develops and commercializes gene‑expression‑profile tests for dermatologic cancers, uveal melanoma, and Barrett’s esophagus. Its flagship product, DecisionDx‑Melanoma, predicts the risk of metastasis in stage I and II cutaneous melanoma by analyzing 31 tumor‑derived genes. The company also offers DecisionDx‑UM for uveal melanoma, DecisionDx‑SCC for cutaneous squamous cell carcinoma, MyPath Melanoma for diagnostically challenging melanocytic lesions, and TissueCypher for predicting progression of high‑grade dysplasia in Barrett’s esophagus. Tests are delivered to physicians, physician assistants, and nurse practitioners to support personalized treatment decisions. Founded in 2007, Castle Biosciences focuses on providing clinically actionable genomic information to improve cancer diagnosis and management.

SiteOne Therapeutics is a San Francisco-based company focused on developing innovative therapeutics and diagnostics aimed at treating acute and chronic pain. The company specializes in creating products that address the limitations of existing pain management therapies, such as nonsteroidal anti-inflammatory drugs (NSAIDs) and opioids. Its lead therapeutic candidates are selective inhibitors of the voltage-gated sodium ion channel Naᵥ1.7, which is essential for the generation and conduction of pain signals. By targeting this specific channel, SiteOne Therapeutics aims to provide more effective and safer pain relief options for healthcare professionals and their patients, particularly in the treatment of neuropathic pain.

SiteOne Therapeutics is a San Francisco-based company focused on developing innovative therapeutics and diagnostics aimed at treating acute and chronic pain. The company specializes in creating products that address the limitations of existing pain management therapies, such as nonsteroidal anti-inflammatory drugs (NSAIDs) and opioids. Its lead therapeutic candidates are selective inhibitors of the voltage-gated sodium ion channel Naᵥ1.7, which is essential for the generation and conduction of pain signals. By targeting this specific channel, SiteOne Therapeutics aims to provide more effective and safer pain relief options for healthcare professionals and their patients, particularly in the treatment of neuropathic pain.

SiteOne Therapeutics is a San Francisco-based company focused on developing innovative therapeutics and diagnostics aimed at treating acute and chronic pain. The company specializes in creating products that address the limitations of existing pain management therapies, such as nonsteroidal anti-inflammatory drugs (NSAIDs) and opioids. Its lead therapeutic candidates are selective inhibitors of the voltage-gated sodium ion channel Naᵥ1.7, which is essential for the generation and conduction of pain signals. By targeting this specific channel, SiteOne Therapeutics aims to provide more effective and safer pain relief options for healthcare professionals and their patients, particularly in the treatment of neuropathic pain.